JMJosé Manuel Moreno-Mirón

José Manuel Moreno-Mirón

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


José Manuel Moreno-Mirón has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Helicobacter pylori in Haematology: Contextualising Established and Emerging Associations

    by José Manuel Moreno-Mirón, Alexa Moreno-Mirón, Guillermo José Ruiz-Argüelles, Robert Peter Gale

  • Open Access

    Pernicious anemia predominates among Mexican adults with vitamin B12 deficiency: clinical and laboratory findings from a tertiary referral center

    by José Manuel Moreno-Mirón, Diana Laura Tavira-Carbajal, Daniela Sánchez-Martínez, Alfonso Orozco-Collazo, Laura Guadalupe Ceja-Ramírez, Fausto Alfredo Rios-Olais, Elena Juventina Tuna-Aguilar, Alvaro Aguayo-Gonzalez

  • Open Access

    Thrombotic Microangiopathy And Hypertensive Emergency After Cocaine Use: A Case Report

    by José Manuel Moreno-Mirón, Juan de Dios Alfonso, Tyler White, Ali Mehdi, Moises Auron

    A patient in her early 60s presented with hypertensive emergency, microangiopathic hemolytic anemia, thrombocytopenia, and non-oliguric acute kidney injury (AKI) after recent cocaine use. The evaluation demonstrated schistocytes, a Coombs-negative hemolysis pattern, and preserved ADAMTS13 activity, making TTP unlikely. Kidney biopsy confirmed acute thrombotic microangiopathy (TMA) and excluded alternative intrinsic renal pathologies. Autoimmune and infectious workup was unrevealing. Although cocaine exposure temporally preceded presentation, malignant hypertension and complement activation may represent overlapping and potentially synergistic mechanisms rather than a single unifying etiology. Blood pressure control improved hemodynamics, but kidney function continued to worsen, and soluble C5b-9 (sC5b-9) was elevated. Eculizumab was initiated empirically after appropriate vaccination due to persistent renal dysfunction despite blood pressure optimization, recognizing that sC5b-9 is not specific for atypical HUS and may be elevated in secondary TMAs. Renal function subsequently stabilized, and the patient remained dialysis-free at three-month follow-up.

  • Open Access

    The Gastro-Intestinal Microbiota in Haematology

    by José Manuel Moreno-Mirón, Guillermo José Ruiz-Argüelles, Moisés Manuel Gallardo-Pérez, Alexa Moreno-Mirón, Ana Paola Rivera-Aguilar, Robert Peter Gale

    Background: The gastro-intestinal microbiota is a key regulator of systemic immunity and inflammatory tone and it contributes to normal haematopoiesis through microbial metabolites, barrier integrity, and host-microbe immune signalling. Disruption of this has been increasingly linked to the development, clinical course, and treatment-related complications of haematological disorders, including clonal haematopoiesis of indeterminate potential (CHIP), leukaemias, and plasma cell neoplasms (PCNs). Summary: This review synthesises current evidence on how gut microbiota composition and function intersect with haematopoietic regulation and haematological disease biology. We summarise proposed mechanisms – including microbe-derived metabolites (e.g., short-chain fatty acids), pattern-recognition receptor signalling, intestinal permeability, and cytokine-mediated inflammation – that may influence haematopoietic stem and progenitor cell behaviour and immune cell differentiation. We then discuss disease-specific associations of dysbiosis with CHIP, leukaemias, and PCN, as well as the impact of common haematology interventions (antibiotics, chemotherapy, immunomodulatory therapies, and transplantation) on microbial ecology and downstream clinical outcomes. Finally, we highlight methodological challenges and outline priorities for longitudinal, mechanistic, and multi-omics studies to enable microbiota-informed risk stratification and therapeutic modulation. Key Messages: (1) The gut microbiota influences haematopoiesis via immune signalling, microbial metabolites, and maintenance of mucosal barrier function. (2) Dysbiosis is associated with CHIP, leukaemias, and PCN, and may contribute through chronic inflammation and altered immune homeostasis. (3) Haematological therapies frequently reshape the microbiota; these changes may affect infection risk, treatment tolerance, and outcomes. (4) Current evidence is largely associative; rigorously designed longitudinal and interventional studies are needed to establish causality and guide clinical translation.